Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT05305482
Recruiting Not applicable

DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial

NCT05305482 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yonsei University
Phase
Not applicable
Started
2022-08-10
Last updated
2025-05-21

Condition(s) studied

Acute Coronary Syndrome

Investigational drug(s) / intervention(s)

Drug-coated stentDrug-eluting stent

Drug-coated stent: The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.

Drug-eluting stent: The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.

Study summary

To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥19 years 2. All subjects who are acceptable candidates for treatment with a drug-coated stent or drug-eluting stent because of acute coronary syndrome 3. Provision of informed consent Exclusion Criteria: 1. Current or potential pregnancy 2. Need of oral anticoagulation therapy 3. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator

Primary outcome measure(s)

  • Patient-Oriented Composite Endpoint (POCE) — At 1 year after randomization
    The composite of all-cause death, MI, or any revascularization

Trial sites (1)

FacilityCityRegionStatus
Yonsei Cardiovascular Hospital, Yonsei University College of Medicine Seoul South Korea Recruiting

More Yonsei University trials in South Korea

Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation Starting soon
In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE) Starting soon
Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study Starting soon
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma Recruiting
Effect of End-inspiratory Pause on Gas Exchange During Mediastinal Mass Excision With CO2 Insufflation and One-lung Ventilation Starting soon

Other trials for the same condition

In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE) Starting soon
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS) Active, not recruiting
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes Recruiting
KOMATE Registry: Korean Multicenter Angioplasty Team Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05305482 on ClinicalTrials.gov ↗ ← All trials in South Korea